Belantamab mafodotin

Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. The antibody portion is Belantamab (HY-P9980), and the drug-linker conjugate for ADC is McMMAF (HY-15578) . Belantamab mafodotin has anti-myeloma activity[1][2].

Product Specifications

CAS Number

[2050232-20-5]

Product Name Alternative

GSK2857916; Belantamab mafodotin-blm

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs)

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/belantamab-mafodotin.html

Purity

99.78

Solubility

10 mM in DMSO

Smiles

[Belantamabmafodotin]

Molecular Weight

149000 (average)

References & Citations

[1]Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2) : a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21 (2) :207-221.|[2]Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80 (15) :1607-1613.